{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:06:52Z","timestamp":1782731212896,"version":"3.54.5"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"peer-reviewed grant from the Berlin Institute of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Men with suspected prostate cancer undergo magnetic resonance imaging (MRI) before biopsy. However, approximately 30%-50% of MRIs are negative (Prostate Imaging\u2013Reporting and Data System [PI-RADS] score 1-2), representing a challenge for MRI resource utilization. This study evaluates prostate cancer polygenic risk scores and clinical markers to optimize MRI utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective study, 500 cancer-suspected men of Western European descent scheduled for MRI (September 2017-December 2022) were enrolled. Exclusions included prior prostate cancer diagnosis, missing serum prostate-specific antigen (PSA), or PSA levels of at least 25\u2009ng\/mL. Patient-specific prostate cancer polygenic risk scores were calculated using genotype data obtained from saliva-derived DNA samples. Participants were grouped as MRI negative and positive (PI-RADS score 3-5). Logistic regression was used to calculate odds ratios (ORs) and to build multivariable risk models, including age, PSA, and polygenic risk scores for MRI positivity. Clinical utility was tested in a holdout test set using decision curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 386 men (median age = 65 years, interquartile range [IQR] = 53-77 years) were eligible for analysis, which showed statistically significant associations between prostate cancer polygenic risk scores (OR = 1.56, 95% confidence interval [CI] = 1.23 to 1.98; P\u2009&amp;lt;\u2009.001) with MRI positivity, while PSA alone did not (OR = 1.17, 95% CI = 0.93 to 1.46; P = .18). The highest net benefit was shown using a multivariable age and prostate cancer polygenic risk score model, increasing the proportion of MRI-positive men by 14% compared with PSA alone (60% and 46%, respectively; P\u2009=\u2009.011).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Genotype-informed risk stratification using prostate cancer polygenic risk scores could increase the proportion of cancer-suspicious findings at MRI, while identifying those who could safely avoid unnecessary MRI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag027","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:44:18Z","timestamp":1769604258000},"page":"1063-1072","source":"Crossref","is-referenced-by-count":2,"title":["Polygenic risk scores for premagnetic resonance imaging risk stratification in men with clinically suspected prostate cancer"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9954-9527","authenticated-orcid":false,"given":"Max P","family":"Fischer","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Laboratory for Statistical Genetics, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Laboratory for Statistical Genetics, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1145-0261","authenticated-orcid":false,"given":"Alice","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Laboratory for Statistical Genetics, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7306-1179","authenticated-orcid":false,"given":"Julia","family":"Kraft","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Laboratory for Statistical Genetics, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6180-506X","authenticated-orcid":false,"given":"Carla M","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Clinic for Nephrology and Intensive Care, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3046-0019","authenticated-orcid":false,"given":"Georg Lukas","family":"Baumg\u00e4rtner","sequence":"additional","affiliation":[{"name":"Department of Radiology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3283","authenticated-orcid":false,"given":"Patrick","family":"Asbach","sequence":"additional","affiliation":[{"name":"Department of Radiology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-5777","authenticated-orcid":false,"given":"Anwar R","family":"Padhani","sequence":"additional","affiliation":[{"name":"Paul Strickland Scanner Centre, Mount Vernon Cancer Centre , Northwood,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Penzkofer","sequence":"additional","affiliation":[{"name":"Department of Radiology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6617-7963","authenticated-orcid":false,"given":"Frank","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Department of Urology, Uro-Oncology, Robot-Assisted and Focal Therapy, University Clinic Magdeburg , Magdeburg,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-8123","authenticated-orcid":false,"given":"Swapnil","family":"Awasthi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Laboratory for Statistical Genetics, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus R","family":"Makowski","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Faculty of Medicine, Technical University of Munich , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-835X","authenticated-orcid":false,"given":"Stephan","family":"Ripke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Laboratory for Statistical Genetics, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]},{"name":"Berlin Institute of Health , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4104-4758","authenticated-orcid":false,"given":"Charlie Alexander","family":"Hamm","sequence":"additional","affiliation":[{"name":"Department of Radiology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin,","place":["Germany"]},{"name":"Berlin Institute of Health , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2026060902505210600_djag027-B1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026060902505210600_djag027-B2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"2026060902505210600_djag027-B3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00345-020-03530-3","article-title":"Role of MRI for the detection of prostate cancer","volume":"39","author":"Wu","year":"2021","journal-title":"World J Urol"},{"key":"2026060902505210600_djag027-B4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","article-title":"Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"key":"2026060902505210600_djag027-B5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.21037\/tau.2017.01.13","article-title":"Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer","volume":"6","author":"Hutchinson","year":"2017","journal-title":"Transl Androl Urol"},{"key":"2026060902505210600_djag027-B6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"2026060902505210600_djag027-B7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073753","article-title":"Hereditary prostate cancer: genes related, target therapy and prevention","volume":"22","author":"Vietri","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026060902505210600_djag027-B8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"key":"2026060902505210600_djag027-B9","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78304","article-title":"Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: a meta-analysis within diverse populations","volume":"11","author":"Chen","year":"2022","journal-title":"Elife"},{"key":"2026060902505210600_djag027-B10","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1158\/1078-0432.CCR-22-1723","article-title":"Family history of prostate and breast cancer integrated with a polygenic risk score identifies men at highest risk of dying from prostate cancer before age 75 years","volume":"28","author":"Plym","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026060902505210600_djag027-B11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstrom","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026060902505210600_djag027-B12","doi-asserted-by":"crossref","first-page":"e1608","DOI":"10.1002\/mpr.1608","article-title":"A tutorial on conducting genome-wide association studies: quality control and statistical analysis","volume":"27","author":"Marees","year":"2018","journal-title":"Int J Methods Psychiatr Res"},{"key":"2026060902505210600_djag027-B13","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","article-title":"ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training","volume":"30","author":"de Rooij","year":"2020","journal-title":"Eur Radiol"},{"key":"2026060902505210600_djag027-B14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ng1847","article-title":"Principal components analysis corrects for stratification in genome-wide association studies","volume":"38","author":"Price","year":"2006","journal-title":"Nat Genet"},{"key":"2026060902505210600_djag027-B15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/ng.3643","article-title":"A reference panel of 64,976 haplotypes for genotype imputation","volume":"48","author":"McCarthy","year":"2016","journal-title":"Nat Genet"},{"key":"2026060902505210600_djag027-B16","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3679","article-title":"Reference-based phasing using the Haplotype reference consortium panel","volume":"48","author":"Loh","year":"2016","journal-title":"Nat Genet"},{"key":"2026060902505210600_djag027-B17","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.3656","article-title":"Next-generation genotype imputation service and methods","volume":"48","author":"Das","year":"2016","journal-title":"Nat Genet"},{"key":"2026060902505210600_djag027-B18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet"},{"key":"2026060902505210600_djag027-B19","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41467-019-09718-5","article-title":"Polygenic prediction via Bayesian regression and continuous shrinkage priors","volume":"10","author":"Ge","year":"2019","journal-title":"Nat Commun"},{"key":"2026060902505210600_djag027-B20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/bju.15535","article-title":"The BARCODE1 pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening","volume":"129","author":"Benafif","year":"2022","journal-title":"BJU Int"},{"key":"2026060902505210600_djag027-B21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk score in screening for prostate cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"N Engl J Med"},{"key":"2026060902505210600_djag027-B22","doi-asserted-by":"crossref","first-page":"894.e1-894","DOI":"10.1016\/j.crad.2019.06.004","article-title":"Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways","volume":"74","author":"Barrett","year":"2019","journal-title":"Clin Radiol"},{"key":"2026060902505210600_djag027-B23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eururo.2011.01.017","article-title":"Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study","volume":"60","author":"Aly","year":"2011","journal-title":"Eur Urol"},{"key":"2026060902505210600_djag027-B24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2012.05.006","article-title":"Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial","volume":"62","author":"Kader","year":"2012","journal-title":"Eur Urol"},{"key":"2026060902505210600_djag027-B25","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.eururo.2013.07.005","article-title":"A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng\/ml","volume":"65","author":"Nordstrom","year":"2014","journal-title":"Eur Urol"},{"key":"2026060902505210600_djag027-B26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021","volume":"80","author":"Van Poppel","year":"2021","journal-title":"Eur Urol"},{"key":"2026060902505210600_djag027-B27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12916-024-03667-7","article-title":"The efficacy of different biomarkers and endpoints to refine referrals for suspected prostate cancer: the TARGET study (Tiered integrAted tests for eaRly diaGnosis of clinically significant ProstatE Tumours)","volume":"22","author":"Lophatananon","year":"2024","journal-title":"BMC Med"},{"key":"2026060902505210600_djag027-B28","doi-asserted-by":"crossref","first-page":"e1002998","DOI":"10.1371\/journal.pmed.1002998","article-title":"Polygenic risk-tailored screening for prostate cancer: a benefit-harm and cost-effectiveness modelling study","volume":"16","author":"Callender","year":"2019","journal-title":"PLoS Med"},{"key":"2026060902505210600_djag027-B29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.euros.2023.05.011","article-title":"How to follow the new EU Council recommendation and improve prostate cancer early detection: the Prostaforum 2022 declaration","volume":"53","author":"Majek","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"2026060902505210600_djag027-B30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"key":"2026060902505210600_djag027-B31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"key":"2026060902505210600_djag027-B32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1148\/radiol.2020190646","article-title":"Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel","volume":"296","author":"Westphalen","year":"2020","journal-title":"Radiology"},{"key":"2026060902505210600_djag027-B33","doi-asserted-by":"crossref","first-page":"15982","DOI":"10.1038\/s41598-020-72544-z","article-title":"Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer","volume":"10","author":"Rudolph","year":"2020","journal-title":"Sci Rep"},{"key":"2026060902505210600_djag027-B34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jamaoncol.2024.5497","article-title":"Oncological safety of MRI-informed biopsy decision-making in men with suspected prostate cancer","volume":"11","author":"Hamm","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026060902505210600_djag027-B35","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41591-023-02277-9","article-title":"Genetically adjusted PSA levels for prostate cancer screening","volume":"29","author":"Kachuri","year":"2023","journal-title":"Nat Med"},{"key":"2026060902505210600_djag027-B36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"2026060902505210600_djag027-B37","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.euo.2024.01.015","article-title":"Magnetic resonance imaging-based prostate cancer screening in carriers of pathogenic germline mutations: interim results from the initial screening round of the Prostate Cancer Genetic Risk Evaluation and Screening Study","volume":"7","author":"Amini","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag027\/66716459\/djag027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/6\/1063\/66716459\/djag027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/6\/1063\/66716459\/djag027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:51:03Z","timestamp":1780987863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/6\/1063\/8455740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag027","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,2,2]]}}}